uic-94003 profile

UIC-94003: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	200104
CHEMBL ID	469086
SCHEMBL ID	1234761
MeSH ID	M0414031

Synonym
tmc-126
206362-00-7
[(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(1s,2r)-1-benzyl-2-hydroxy-3-[isobutyl-(4-methoxyphenyl)sulfonyl-amino]propyl]carbamate
carbamic acid, [(1s,2r)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl ester
uic-pi
tmc126
uic-94003
tmc 126
uic 94003
(3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl n-[(2s,3r)-3-hydroxy-4-[(4-methoxybenzene)(2-methylpropyl)sulfonamido]-1-phenylbutan-2-yl]carbamate
bdbm9236
DJR ,
(3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(1s,2r)-1-benzyl-2-hydroxy-3-{isobutyl[(4-methoxyphenyl)sulfonyl]amino}propyl]carbamate
2I4V
2I4U
[(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate
CHEMBL469086
carbamic acid, ((1s,2r)-2-hydroxy-3-(((4-methoxyphenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)propyl)-, (3r,3as,6ar)-hexahydrofuro(2,3-b)furan-3-yl ester
3I7E
SCHEMBL1234761
(3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(1s,2r)-1-benzyl-2-hydroxy-3-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}propyl]carbamate
hexahydrofuro[2,3-b]furan-3-yl hydrogen {3-hydroxy-4-[(4-methoxybenzene-1-sulfonyl)(2-methylpropyl)amino]-1-phenylbutan-2-yl}carbonimidate
DTXSID60942831
Q27459383

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, Protease	Human immunodeficiency virus type 1 (BRU ISOLATE)	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, Protease	Human immunodeficiency virus type 1 (BRU ISOLATE)	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain A, HIV-1 protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Chain B, HIV-1 protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0000	0.0000	AID977610
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (BRU ISOLATE)	Ki	0.0000	0.0000	0.0828	3.3000	AID1796306; AID1799362
Protease	Human immunodeficiency virus 1	Ki	0.0011	0.0000	0.0443	3.1000	AID160442
Protease	Human immunodeficiency virus 1	IC50 (µMol)	0.0014	0.0000	0.8176	9.8500	AID415236
Protease	Human immunodeficiency virus 1	Ki	0.0000	0.0000	0.0284	1.1000	AID311574; AID328062; AID391263; AID415236; AID446190
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay ID	Title	Year	Journal	Article
AID311575	Antiviral activity against HIV1 in CEM cells	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
AID236641	Maximum plasma concentration in dog after 80 mg/kg oral administration	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID415238	Antiviral activity against protease inhibitor resistant HIV1 isolates	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
AID415236	Inhibition of HIV1 protease	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
AID446190	Inhibition of HIV1 protease	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID311574	Inhibition of HIV1 protease	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
AID160442	Inhibitory activity against HIV-1 protease	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
AID237955	Percentage of remaining compound after 30 min incubation in rat liver microsomes was determined as metabolic stability	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID236937	Half-life in dog after 80 mg/kg oral administration	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID236972	Time to reach maximum concentration in dog after 80 mg/kg oral administration	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID237954	Percentage of remaining compound after 30 min incubation in dog liver microsomes was determined as metabolic stability	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID1465009	Antiviral activity against HIV-1 harboring protease I50V mutant	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
AID391264	Antiviral activity against HIV1 LAI in human MT2 cells assessed as inhibition of virus-induced cytopathic effect	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID391263	Inhibition of HIV1 protease	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID237560	Area under concentration time curve value in dog after 80 mg/kg oral administration	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID1465008	Inhibition of wild-type HIV-1 protease	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
AID249504	Effective concentration against PI-Resistant HIV strain (M2)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID328063	Antiviral activity against HIV1 LAI in MT2 cells	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
AID1482910	Antiviral activity against HIV1 Lai infected in human MT2 cells	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
AID249505	Effective concentration against PI-Resistant HIV strain (M3)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID249503	Effective concentration against PI-Resistant HIV strain (M1)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID328062	Inhibition of HIV1 protease dimerization in MT2 cells	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
AID446191	Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID249507	Effective concentration against PI-Resistant HIV strain (M5)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID328067	Inhibition of HIV1 protease dimerization in MT2 cells at 1 uM	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
AID105016	Compound was tested for the inhibition of HIV-1 in MT-4 human T-lymphoid cells infected with IIIB isolate	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
AID246282	Effective concentration against human immunodeficiency virus type 1 strains; (0.3-0.5 nM)	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	New approaches toward anti-HIV chemotherapy.
AID237956	Percentage of remaining compound after 30 min incubation in human liver microsomes was determined as metabolic stability	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID1482908	Inhibition of HIV1 protease expressed in Escherichia coli using 2-aminobenzoyl-Thr-Ile-Nle-Phe(p-N02)-Gln-Arg-NH as substrate preincubated for 5 to 10 mins followed by substrate addition measured after 1 hr by fluorescence assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
AID249509	Effective concentration as average activity on mutant HIV panel (AVMUT)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID249506	Effective concentration against PI-Resistant HIV strain (M4)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID249508	Effective concentration of against HIV Wild Type (IIIB) strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID1796306	Protease Inhibition Assay from Article 10.1016/s0960-894x(02)00300-1: \\Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.\\	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.
AID1799362	Enzyme Inhibition Assay (Ki) and Antiviral Activity Assay (EC50/IC50) from Article 10.1021/jm900695w: \\Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease in	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2006	Journal of molecular biology, Oct-27, Volume: 363, Issue:3	Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
AID1811	Experimentally measured binding affinity data derived from PDB	2006	Journal of molecular biology, Oct-27, Volume: 363, Issue:3	Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (5.56)	18.2507
2000's	13 (72.22)	29.6817
2010's	3 (16.67)	24.3611
2020's	1 (5.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (22.22%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (77.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbamates [no description available]	3.52	2	amino-acid anion
urethane [no description available]	4.39	6	carbamate ester	fungal metabolite; mutagen
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.44	2	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.01	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	3.12	1	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
amprenavir [no description available]	5.02	7	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
lopinavir [no description available]	3.85	3	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
fosamprenavir fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.	3.12	1	sulfonamide	prodrug
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	2.15	1	carbohydrazide	antiviral drug; HIV protease inhibitor
atazanavir sulfate Atazanavir Sulfate: An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.	3.12	1	organic sulfate salt
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	5.26	9	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.34	3	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	5.03	7	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
om99-2 OM99-2: eight-residue memapsin 2 inhibitor; structure in first source	3.14	1
l 739594 L 739594: structure given in first source	4.33	3
grl 98065 [no description available]	3.82	3
pl 100 PL 100: inhibits HIV-1 protease; structure in first source	3.13	1
maraviroc [no description available]	3.12	1	tropane alkaloid
vicriviroc vicriviroc: structure in first source	3.12	1	(trifluoromethyl)benzenes
tak-220 TAK-220: structure in first source	3.12	1
dpc 083 [no description available]	3.12	1
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	4.04	4	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
brecanavir brecanavir: HIV protease inhibitor	2.03	1
s 1360 [no description available]	3.12	1
enfuvirtide Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.	3.12	1
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	2.03	1	sulfonamide	antiviral drug; HIV protease inhibitor
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	3.12	1

Condition	Relationship Strength	Studies
HIV Coinfection [description not available]	4.85	5
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	4.85	5
Acute Confusional Senile Dementia [description not available]	2.96	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.96	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.93	1

uic-94003

Description

Cross-References

Synonyms (24)

Protein Targets (17)

Inhibition Measurements

Bioassays (37)

Research

Studies (18)

Study Types

uic-94003

Description

Cross-References

Synonyms (24)

Protein Targets (17)

Inhibition Measurements

Bioassays (37)

Research

Studies (18)

Study Types

Related Drugs (27)

Related Conditions (5)